As brain health becomes an ever greater concern for people of all ages, the nation’s largest senior living provider is now guiding its residents on developing and putting into practice personalized brain health plans. Brookdale devised the new resident program with the help of a neuropsychologist specializing in brain health. The company is putting it into place at its independent and assisted living communities across the country.
Through the new initiative, Brookdale’s residents will be offered a four-session course that explains key factors in brain health through classroom learning and hands-on activities. Each participant will be guided on creating an individual brain health plan to use on a daily basis. The course was developed with the assistance of Dr. Paul Nussbaum, who is Board Certified in clinical and geropsychology with a specialty in neuropsychology. An adjunct professor of neurological surgery at the University of Pittsburgh, he is the author of “Save Your Brain.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7722157-brookdale-brain-health/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Kent Displays announced today it is expanding global distribution and developing new product features for the Boogie Board Paperless LCD Writing Tablet based on heavy demand. Kent Displays subsidiary Improv Electronics launched the Boogie Board tablet in the United States in January 2010. It is the first paperless writing tablet to utilize a pressure-sensitive, Reflex™ LCD from Kent Displays for its writing surface.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/kentdisplays/42066/
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
Based on its recent analysis of the Satellite Network Management market, Frost & Sullivan recognizes Spacenet Inc., a leading provider of broadband network solutions, with the 2011 North America Frost & Sullivan Award for New Product Innovation. The company is commended for developing the innovative Prysm Pro.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/spacenet/49003/
http://igetitapps.com/ i Get It offers some of the best educational apps for iPad, iPhone and iPod Touch, autism apps, and iPad apps for special needs kids. i Get It applications are designed to support language skill development and facilitate cognitive growth through building language skills. Typically developing young children and individuals with developmental delays, such as PDD-NOS, autism, down syndrome or TBI will benefit from these interactive applications. Autism apps have been recently featured on TV shows as a great way of communication for people whose condition prevents them from speaking. i Get It apps have been featured on AutismSpeaks.org, Snapps4kids.com, A4cwsn and many others. Please go to http://igetitapps.com/ to see all our apps.
ART SCHOOLS
The Arts & Learning Conservatory based in Santa Ana, CA has been one of the leading arts schools for kids between 5 to 17 years since 2004. Our experienced professionals provide quality teaching in the art school to students for building a unique artistic vision in arts and craft . Our arts school amplifies the ability of student in art and craft developing their artistic abilities in numerous ways.
During the third quarter, we were again able to capture the benefits of AEGON’s strategic priorities, resulting in solid earnings growth, improved profitability of sales, lower expenses and a continued strong capital position. Our franchise remains healthy, as evidenced by the particularly high level of At-Retirement and pension sales. At the same time, we are making essential investments to reshape our businesses in both our established and developing markets to respond effectively to the changing conditions and new realities. Although there are signs of gradually improving market conditions, there remains considerable uncertainty in the general economic environment. Consequently, we believe it is prudent and necessary to maintain a sufficient financial buffer while at the same time adhering to our strict risk and pricing discipline. The steps we are taking across our organization to get closer to our end customers, combined with the strength of our current position, give us full confidence in the prospects for our business going forward.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58637-aegon-quarter-3-results
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
http://www.freeinfinitepossibilities.com http://www.freeinfinitepossibilities.com/path-to-success-tips/ Free Infinite Possibilities is about your self development and your awareness of self. Its about developing the most important relationship you will ever have - the relationship with yourself. 5 Success tips on your path to success was formulated so you can start thinking about the framework and the strategies you need to bew the best you that you can be.
